Market by Procedure (Laparoscopy, Orthopedic Surgery, Cardiovascular, Obstetrics and Gynecology, Wound Closure, Plastic & Reconstructive Surgery, Thoracic Surgery, Microvascular, Urology, Neurosurgery, Other Procedures) Type of Infection (Superficial Incisional SSI, Deep Incisional SSI, Organ or Space SSI) Industry Vertical (Hospitals, Ambulatory Surgical Centers) Product (Disinfectants, Manual Reprocessors Solutions, Surgical Drapes, Surgical Gloves, Skin Preparation Solutions, Surgical Irrigation, Surgical Scrubs, Hair Clippers, Medical Nonwovens, Other Products) and Country Outlook | Forecast 2024-2032
Triton’s research report states that the Middle East and Africa surgical site infection control market is estimated to register a CAGR of 4.56% during the forecast period 2024-2032.
Report scope can be customized per your requirements - Request Free Sample Report
The surgical site infection (SSI) control market’s development in the Middle East and Africa (MEA) is accelerated by rising healthcare awareness, government initiatives, and international collaborations aimed at improving healthcare infrastructure. The World Health Organization (WHO) and various regional health ministries have been actively involved in initiatives to reduce SSIs, which are a significant cause of morbidity and mortality. In countries like Saudi Arabia and South Africa, there has been a significant push towards improving hospital hygiene and infection control measures supported by government funding and international partnerships. Governments are also investing in the training of healthcare workers and the adoption of advanced sterilization technologies, which are expected to drive the surgical site infection control market further.
The countries analyzed in this region include:
Saudi Arabia leads the regional market, obtaining $66.9 million in 2023
The growth of the surgical site infection control market in Saudi Arabia is strongly driven by the government’s Vision 2030 initiative, which aims to modernize the healthcare sector and improve patient safety.
The Saudi Ministry of Health has implemented stringent guidelines and infection control protocols in hospitals to reduce the incidence of surgical site infections (SSIs). The introduction of advanced sterilization techniques, antimicrobial dressings, and preventive measures are increasingly being adopted across healthcare facilities.
The Saudi Centers for Disease Control and Prevention provides specific guidelines for SSI prevention, including the use of prophylactic antibiotics, proper hand hygiene, and enhanced sterilization protocols. These guidelines have been widely adopted, leading to increased demand for infection control products and technologies.
Market Forecast for Turkey
In Turkey, the surgical site infection (SSI) control market is fueled by healthcare awareness and government initiatives aimed at improving patient safety. In 2022, surgical site infections remained a critical concern for Turkey’s healthcare system, particularly in procedures like cesarean sections and other high-frequency surgeries. The Ministry of Health in Turkey has been actively working on reducing healthcare-associated infections through various programs, including mandatory infection control measures in hospitals and the implementation of international best practices. The market is further supported by the increasing number of hospitals and the growing use of minimally invasive surgeries, which require stringent infection prevention measures. The market is expected to continue its growth trajectory owing to the government’s commitment to improving healthcare outcomes through better infection control protocols.
The market segmentation includes industry vertical, procedure, type of infection, and product. The industry vertical section consists of hospitals and ambulatory surgical centers.
Surgical site infections (SSIs) account for approximately 15% of all hospital-acquired infections, making them the most common infection among surgical patients. These infections significantly extend postoperative hospital stays, increase healthcare costs, elevate the likelihood of readmission, and compromise patient outcomes. SSIs, which occur at or near surgical incisions within 30 days after surgery, contribute heavily to surgical complications and mortality annually.
Contender Analysis in the Surgical Site Infection Control Market:
3M is a diversified technology firm with operations across multiple industries, including industrial, safety and graphics, electronics and energy, healthcare, and consumer markets. Headquartered in Saint Paul, Minnesota, 3M has a global presence in the United States, Europe, the Middle East and Africa (EMEA), and the Asia Pacific. The company operates through five main business segments: industrial, safety and graphics, health care, electronics and energy, and consumer. The company also specializes in precision grinding technology for intricate industrial applications, and it develops advanced technical ceramics for use in sectors like automotive, oil and gas, solar, electronics, and defense.
Other companies in the market consist of American Polyfilm Inc, Ansell Limited, Belimed Life Science AG, and Gama Healthcare.
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the surgical site infection control market revenue growth in the Middle East and Africa and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the MEA surgical site infection control market’s growth during the upcoming years
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. MIDDLE
EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT
ANALYSIS ON THE SURGICAL SITE INFECTION CONTROL MARKET
2.1.1. COVID-19
IMPACT
2.2. PORTER’S
FIVE FORCES ANALYSIS
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTES
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. THREAT
OF COMPETITIVE RIVALRY
2.3. KEY
MARKET STRATEGIES
2.3.1. PRODUCT
LAUNCHES
2.3.2. ACQUISITIONS
2.3.3. BUSINESS
DIVESTITURES & EXPANSIONS
2.4. MARKET
DRIVERS
2.4.1. ESCALATING
INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
2.4.2. GROWING
GERIATRIC POPULATION
2.4.3. REGULATORY
GUIDELINES FOR PREVENTING HOSPITAL-ACQUIRED INFECTION
2.5. MARKET
CHALLENGES
2.5.1. INCREASE
IN OUTPATIENT TREATMENT
2.5.2. SURGE
IN MEDICAL WASTE DUE TO THE USE OF DISPOSABLE MEDICAL ITEMS
2.5.3. INSUFFICIENT
AWARENESS REGARDING HOSPITAL-ACQUIRED INFECTIONS
2.6. MARKET
OPPORTUNITIES
2.6.1. GROWTH
OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
2.6.2. RISE
IN SURGICAL PROCEDURE RATES
2.6.3. TECHNOLOGICAL
ADVANCEMENTS IN PREVENTING SURGICAL SITE INFECTIONS
2.7. ANALYST
PERSPECTIVE
3. MIDDLE
EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY PROCEDURE
3.1. LAPAROSCOPY
3.2. ORTHOPEDIC
SURGERY
3.3. CARDIOVASCULAR
3.4. OBSTETRICS
AND GYNECOLOGY
3.5. WOUND
CLOSURE
3.6. PLASTIC
& RECONSTRUCTIVE SURGERY
3.7. THORACIC
SURGERY
3.8. MICROVASCULAR
3.9. UROLOGY
3.10. NEUROSURGERY
3.11. OTHER
PROCEDURES
4. MIDDLE
EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY TYPE OF INFECTION
4.1. SUPERFICIAL
INCISIONAL SSI
4.2. DEEP
INCISIONAL SSI
4.3. ORGAN
OR SPACE SSI
5. MIDDLE
EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY INDUSTRY VERTICAL
5.1. HOSPITALS
5.2. AMBULATORY
SURGICAL CENTERS
6. MIDDLE
EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY PRODUCT
6.1. DISINFECTANTS
6.1.1. SKIN
DISINFECTANTS
6.1.2. HAND
DISINFECTANTS
6.2. MANUAL
REPROCESSORS SOLUTIONS
6.3. SURGICAL
DRAPES
6.4. SURGICAL
GLOVES
6.5. SKIN
PREPARATION SOLUTIONS
6.6. SURGICAL
IRRIGATION
6.7. SURGICAL
SCRUBS
6.8. HAIR
CLIPPERS
6.9. MEDICAL
NONWOVENS
6.10. OTHER
PRODUCTS
7. MIDDLE
EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY COUNTRY OUTLOOK
7.1. MIDDLE
EAST AND AFRICA
7.1.1. COUNTRY
ANALYSIS
7.1.1.1. UNITED
ARAB EMIRATES
7.1.1.1.1. UNITED
ARAB EMIRATES SURGICAL SITE INFECTION CONTROL MARKET FORECAST &
PROSPECTS
7.1.1.2. SAUDI
ARABIA
7.1.1.2.1. SAUDI
ARABIA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.3. TURKEY
7.1.1.3.1. TURKEY
SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.4. SOUTH
AFRICA
7.1.1.4.1. SOUTH
AFRICA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.5. ISRAEL
7.1.1.5.1. ISRAEL
SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.6. REST
OF MIDDLE EAST & AFRICA
7.1.1.6.1. REST
OF MIDDLE EAST & AFRICA SURGICAL SITE INFECTION CONTROL MARKET FORECAST
& PROSPECTS
8. COMPETITIVE
LANDSCAPE
8.1. AMERICAN
POLYFILM INC
8.1.1. OVERVIEW
8.1.2. PORTFOLIO
8.1.3. KEY
STRENGTHS
8.1.4. KEY
CHALLENGES
8.2. 3M
8.2.1. OVERVIEW
8.2.2. PORTFOLIO
8.2.3. KEY
STRENGTHS
8.2.4. KEY
CHALLENGES
8.3. ANSELL
LIMITED
8.3.1. OVERVIEW
8.3.2. PORTFOLIO
8.3.3. KEY
STRENGTHS
8.3.4. KEY
CHALLENGES
8.4. BELIMED
LIFE SCIENCE AG
8.4.1. OVERVIEW
8.4.2. PORTFOLIO
8.4.3. KEY
STRENGTHS
8.4.4. KEY
CHALLENGES
8.5. BECTON,
DICKINSON AND COMPANY (BD)
8.5.1. OVERVIEW
8.5.2. PORTFOLIO
8.5.3. KEY
STRENGTHS
8.5.4. KEY
CHALLENGES
8.6. BIOMERIEUX
SA
8.6.1. OVERVIEW
8.6.2. PORTFOLIO
8.6.3. KEY
STRENGTHS
8.6.4. KEY
CHALLENGES
8.7. GETINGE
AB
8.7.1. OVERVIEW
8.7.2. PORTFOLIO
8.7.3. KEY
STRENGTHS
8.7.4. KEY
CHALLENGES
8.8. GAMA
HEALTHCARE
8.8.1. OVERVIEW
8.8.2. PORTFOLIO
8.8.3. KEY
STRENGTHS
8.8.4. KEY
CHALLENGES
8.9. JOHNSON
& JOHNSON
8.9.1. OVERVIEW
8.9.2. PORTFOLIO
8.9.3. KEY
STRENGTHS
8.9.4. KEY
CHALLENGES
8.10. SOTERA
HEALTH LLC
8.10.1. OVERVIEW
8.10.2. PORTFOLIO
8.10.3. KEY
STRENGTHS
8.10.4. KEY
CHALLENGES
8.11. KIMBERLY-CLARK
CORPORATION
8.11.1. OVERVIEW
8.11.2. PORTFOLIO
8.11.3. KEY
STRENGTHS
8.11.4. KEY
CHALLENGES
8.12. STERIS
CORPORATION
8.12.1. OVERVIEW
8.12.2. PORTFOLIO
8.12.3. KEY
STRENGTHS
8.12.4. KEY
CHALLENGES
8.13. STRYKER
CORPORATION
8.13.1. OVERVIEW
8.13.2. PORTFOLIO
8.13.3. KEY
STRENGTHS
8.13.4. KEY
CHALLENGES
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032
(IN $ MILLION)
TABLE 2: LIST OF PRODUCT
LAUNCHES
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF BUSINESS
DIVESTITURES & EXPANSIONS
TABLE 5: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2024-2032 (IN $
MILLION)
TABLE 6: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2024-2032
(IN $ MILLION)
TABLE 7: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN
$ MILLION)
TABLE 8: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2024-2032 (IN $
MILLION)
TABLE 9: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032
(IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCES
ANALYSIS
FIGURE 2: MIDDLE EAST AND
AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2023 & 2032
(IN %)
FIGURE 3: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY LAPAROSCOPY, 2024-2032 (IN $
MILLION)
FIGURE 4: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY ORTHOPEDIC SURGERY, 2024-2032 (IN $
MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY CARDIOVASCULAR, 2024-2032 (IN $
MILLION)
FIGURE 6: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY OBSTETRICS AND GYNECOLOGY, 2024-2032
(IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY WOUND CLOSURE, 2024-2032 (IN $
MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY PLASTIC & RECONSTRUCTIVE
SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY THORACIC SURGERY, 2024-2032 (IN $
MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY MICROVASCULAR, 2024-2032 (IN $
MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY UROLOGY, 2024-2032 (IN $
MILLION)
FIGURE 12: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY NEUROSURGERY, 2024-2032 (IN $
MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PROCEDURES, 2024-2032 (IN $
MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2023 & 2032
(IN %)
FIGURE 15: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SUPERFICIAL INCISIONAL SSI,
2024-2032 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY DEEP INCISIONAL SSI, 2024-2032 (IN $
MILLION)
FIGURE 17: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY ORGAN OR SPACE SSI, 2024-2032 (IN $
MILLION)
FIGURE 18: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2023 & 2032
(IN %)
FIGURE 19: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE 20: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY AMBULATORY SURGICAL CENTERS,
2024-2032 (IN $ MILLION)
FIGURE 21: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2023 & 2032 (IN %)
FIGURE 22: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2024-2032 (IN $
MILLION)
FIGURE 23: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2023 & 2032 (IN
%)
FIGURE 24: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN DISINFECTANTS, 2024-2032 (IN $
MILLION)
FIGURE 25: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY HAND DISINFECTANTS, 2024-2032 (IN $
MILLION)
FIGURE 26: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY MANUAL REPROCESSORS SOLUTIONS,
2024-2032 (IN $ MILLION)
FIGURE 27: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL DRAPES, 2024-2032 (IN $
MILLION)
FIGURE 28: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL GLOVES, 2024-2032 (IN $
MILLION)
FIGURE 29: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN PREPARATION SOLUTIONS,
2024-2032 (IN $ MILLION)
FIGURE 30: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL IRRIGATION, 2024-2032 (IN $
MILLION)
FIGURE 31: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL SCRUBS, 2024-2032 (IN $
MILLION)
FIGURE 32: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY HAIR CLIPPERS, 2024-2032 (IN $
MILLION)
FIGURE 33: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY MEDICAL NONWOVENS, 2024-2032 (IN $
MILLION)
FIGURE 34: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $
MILLION)
FIGURE 35: MIDDLE EAST AND AFRICA
SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN
%)
FIGURE 36: UNITED ARAB
EMIRATES SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 37: SAUDI ARABIA
SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: TURKEY SURGICAL
SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 39: SOUTH AFRICA
SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 40: ISRAEL SURGICAL
SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 41: REST OF MIDDLE EAST
& AFRICA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)